Sihuan Pharmaceutical Holdings Group Ltd. - Product Pipeline Review – 2015 Is Released Sihuan Pharmaceutical Holdings Group Ltd. - Product Pipeline Review - 2015 Summary Global Markets Direct s, Sihuan Pharmaceutical Holdings Group Ltd. - Product Pipeline Review - 2015, provides an overview of the Sihuan Pharmaceutical Holdings Group Ltd. s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Sihuan Pharmaceutical Holdings Group Ltd.s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-inclass products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Sihuan Pharmaceutical Holdings Group Ltd. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Sihuan Pharmaceutical Holdings Group Ltd.s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Sihuan Pharmaceutical Holdings Group Ltd.s pipeline products Reasons to buy - Evaluate Sihuan Pharmaceutical Holdings Group Ltd.s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Sihuan Pharmaceutical Holdings Group Ltd. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Sihuan Pharmaceutical Holdings Group Ltd. s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Sihuan Pharmaceutical Holdings Group Ltd. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Sihuan Pharmaceutical Holdings Group Ltd. - Develop and 1
design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Sihuan Pharmaceutical Holdings Group Ltd. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues Browse Complete Report with TOC http://www.idatainsights.com/reports-landingpage.php?id=179153/sihuan-pharmaceutical-holdings-group-ltd-product-pipeline-review-2015 To Get Sample Copy of Report visit http://www.idatainsights.com/reports-landingpage.php?id=179153/sihuan-pharmaceutical-holdings-group-ltd-product-pipeline-review-2015 Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Sihuan Pharmaceutical Holdings Group Ltd. Snapshot 6 Sihuan Pharmaceutical Holdings Group Ltd. Overview 6 Key Information 6 Key Facts 6 Sihuan Pharmaceutical Holdings Group Ltd. - Research and Development Overview 7 Key Therapeutic Areas 7 Sihuan Pharmaceutical Holdings Group Ltd. - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Partnered Products 12 Partnered Products/Combination Treatment Modalities 13 Sihuan Pharmaceutical Holdings Group Ltd. - Pipeline Products Glance 14 Sihuan Pharmaceutical Holdings Group Ltd. - Late Stage Pipeline Products 14 Phase III Products/Combination Treatment Modalities 14 Sihuan Pharmaceutical Holdings Group Ltd. - Clinical Stage Pipeline Products 15 2
Phase II Products/Combination Treatment Modalities 15 Phase I Products/Combination Treatment Modalities 16 Sihuan Pharmaceutical Holdings Group Ltd. - Early Stage Pipeline Products 17 IND/CTA Filed Products/Combination Treatment Modalities 17 Sihuan Pharmaceutical Holdings Group Ltd. - Unknown Stage Pipeline Products 18 Unknown Products/Combination Treatment Modalities 18 Sihuan Pharmaceutical Holdings Group Ltd. - Drug Profiles 19 Phencynonate Hydrochloride 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Cinepazide Mesylate 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 cyclosporine 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Anaprazole Sodium 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 3
Benapenem 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Imigliptin Dihydrochloride 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 JK-05 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 KBP-5209 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Janagliflozin 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Pinoxacin Hydrochloride 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 4
tylerdipine hydrochloride 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 BR-01 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Sihuan Pharmaceutical Holdings Group Ltd. - Pipeline Analysis 33 Sihuan Pharmaceutical Holdings Group Ltd. - Pipeline Products by Target 33 Sihuan Pharmaceutical Holdings Group Ltd. - Pipeline Products by Route of Administration 35 Sihuan Pharmaceutical Holdings Group Ltd. - Pipeline Products by Molecule Type 36 Sihuan Pharmaceutical Holdings Group Ltd. - Pipeline Products by Mechanism of Action 37 Sihuan Pharmaceutical Holdings Group Ltd. - Recent Pipeline Updates 39 Sihuan Pharmaceutical Holdings Group Ltd. - Dormant Projects 42 Sihuan Pharmaceutical Holdings Group Ltd. - Discontinued Pipeline Products 43 Discontinued Pipeline Product Profiles 43 cyclosporine 43 Sihuan Pharmaceutical Holdings Group Ltd. - Locations And Subsidiaries 44 Head Office 44 Other Locations & Subsidiaries 44 Appendix 45 Methodology 45 5
Coverage 45 Secondary Research 45 Primary Research 45 Expert Panel Validation 45 Contact Us 45 Disclaimer 46" width="80" height="40" />Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Sihuan Pharmaceutical Holdings Group Ltd. Snapshot 6 Sihuan Pharmaceutical Holdings Group Ltd. Overview 6 Key Information 6 Key Facts 6 Sihuan Pharmaceutical Holdings Group Ltd. - Research and Development Overview 7 Key Therapeutic Areas 7 Sihuan Pharmaceutical Holdings Group Ltd. - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Partnered Products 12 Partnered Products/Combination Treatment Modalities 13 Sihuan Pharmaceutical Holdings Group Ltd. - Pipeline Products Glance 14 Sihuan Pharmaceutical Holdings Group Ltd. - Late Stage Pipeline Products 14 Phase III Products/Combination Treatment Modalities 14 Sihuan Pharmaceutical Holdings Group Ltd. - Clinical Stage Pipeline Products 15 6
Phase II Products/Combination Treatment Modalities 15 Phase I Products/Combination Treatment Modalities 16 Sihuan Pharmaceutical Holdings Group Ltd. - Early Stage Pipeline Products 17 IND/CTA Filed Products/Combination Treatment Modalities 17 Sihuan Pharmaceutical Holdings Group Ltd. - Unknown Stage Pipeline Products 18 Unknown Products/Combination Treatment Modalities 18 Sihuan Pharmaceutical Holdings Group Ltd. - Drug Profiles 19 Phencynonate Hydrochloride 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Cinepazide Mesylate 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 cyclosporine 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Anaprazole Sodium 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 7
Benapenem 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Imigliptin Dihydrochloride 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 JK-05 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 KBP-5209 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Janagliflozin 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Pinoxacin Hydrochloride 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 8
tylerdipine hydrochloride 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 BR-01 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Sihuan Pharmaceutical Holdings Group Ltd. - Pipeline Analysis 33 Sihuan Pharmaceutical Holdings Group Ltd. - Pipeline Products by Target 33 Sihuan Pharmaceutical Holdings Group Ltd. - Pipeline Products by Route of Administration 35 Sihuan Pharmaceutical Holdings Group Ltd. - Pipeline Products by Molecule Type 36 Sihuan Pharmaceutical Holdings Group Ltd. - Pipeline Products by Mechanism of Action 37 Sihuan Pharmaceutical Holdings Group Ltd. - Recent Pipeline Updates 39 Sihuan Pharmaceutical Holdings Group Ltd. - Dormant Projects 42 Sihuan Pharmaceutical Holdings Group Ltd. - Discontinued Pipeline Products 43 Discontinued Pipeline Product Profiles 43 cyclosporine 43 Sihuan Pharmaceutical Holdings Group Ltd. - Locations And Subsidiaries 44 Head Office 44 Other Locations & Subsidiaries 44 Appendix 45 Methodology 45 9
Coverage 45 Secondary Research 45 Primary Research 45 Expert Panel Validation 45 Contact Us 45 Disclaimer 46 Read More http://www.idatainsights.com/reports-landing-page.php?id=179153/sihuanpharmaceutical-holdings-group-ltd-product-pipeline-review-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line. ContactUs: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.
10